Skip to main content
Log in

Protein Kinase CK2 Content in GL261 Mouse Glioblastoma

  • Short Communication
  • Published:
Pathology & Oncology Research

Abstract

Glioblastoma (GBM) is the most prevalent and aggressive human glial tumour with a median survival of 14–15 months. Temozolomide (TMZ) is the standard chemotherapeutic choice for GBM treatment. Unfortunately, chemoresistence always ensues with concomitant tumour regrowth. Protein kinase CK2 (CK2) contributes to tumour development, proliferation, and suppression of apoptosis in cancer and it is overexpressed in human GBM. Targeting CK2 in GBM treatment may benefit patients. With this translational perspective in mind, we have studied the CK2 expression level by Western blot analysis in a preclinical model of GBM: GL261 cells growing orthotopically in C57BL/6 mice. The expression level of the CK2 catalytic subunit (CK2α) was higher in tumour (about 4-fold) and in contralateral brain parenchyma (more than 2-fold) than in normal brain parenchyma (p < 0.05). In contrast, no significant changes were found in CK2 regulatory subunit (CK2β) expression, suggesting an increased unbalance of CK2α/CK2β in GL261 tumours with respect to normal brain parenchyma, in agreement with a differential role of these two subunits in tumours.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Abbreviations

GBM:

Glioblastoma

CK2:

Protein kinase CK2

TMZ:

Temozolomide

References

  1. Buckner JC (2003) Factors influencing survival in high-grade gliomas. Semin Oncol 30(6 Suppl 19):10–14

    Article  PubMed  Google Scholar 

  2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 10;352(10):987–996.

  3. Huang Z, Cheng L, Guryanova OA, Wu Q, Bao S (2010) Cancer stem cells in glioblastoma - molecular signalling and therapeutic targeting. Protein Cell 1(7):638–655

    Article  CAS  PubMed  Google Scholar 

  4. Ausman JI, Shapiro WR, Rall DP (1970) Studies on the chemotherapy of experimental brain tumors: development of an experimental model. Cancer Res 30:2394–2400

    CAS  PubMed  Google Scholar 

  5. Szatmári T, Lumniczky K, Désaknai S, Trajcevski S, Hidvégi EJ, Hamada H, et al. (2006) Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy. Cancer Sci 97(6):546–553

    Article  PubMed  Google Scholar 

  6. Delgado-Goñi T, Julià-Sapé M, Candiota AP, Pumarola M, Arús C (2014) Molecular imaging coupled to pattern recognition distinguishes response to temozolomide in preclinical glioblastoma. NMR Biomed 27(11):1333–1345

    Article  PubMed  Google Scholar 

  7. Ducan JS, Litchfield DW (2008) Too much of a good thing: the role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2. Biochim Biophys Acta 1784:33–47

    Article  Google Scholar 

  8. Ruzzene M, Pinna LA (2010) Addiction to protein kinase CK2: a common denominator of diverse cancer Cells? Biochim Biophys Acta 1804(3):499–504

    Article  CAS  PubMed  Google Scholar 

  9. Dixit D, Sharma V, Ghosh S, Mehta VS, Sen E (2012) Inhibition of Casein kinase-2 induces p53-dependent cell cycle arrest and sensitizes glioblastoma cells to tumor necrosis factor (TNFα)-induced apoptosis through SIRT1 inhibition. Cell Death Dis 3:e271

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Ji H, Lu Z (2013) The role of protein kinase CK2 in glioblastoma development. Clin Cancer Res 19:6335–6337

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Münstermann U, Fritz G, Seitz G, Yiping L, Schneider HR, Issinger OG (1990) Casein kinase II is elevated in solid human tumours and rapidly proliferating non-neoplastic tissue. Eur J Biochem 189:251–257

    Article  PubMed  Google Scholar 

  12. Cozza G, Girardi C, Ranchio A, Liolli G, Sarno S, Orzeszko A, et al. (2014) Cell-permeable dual inhibitors of protein kinases CK2 and PIM-1: structural features and pharmacological potential. Cell Mol Life Sci 71:3173–3185

    Article  CAS  PubMed  Google Scholar 

  13. Kim J, Hwan KS (2013) CK2 inhibitor CX-4945 blocks TGF-beta1- induced epithelial-to mesenchymal transition in A549 human lung adenocarcinoma cells. PLoS One 8(9):e74342

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Simoes RV, Garcia-Martin ML, Cerdan S, Arus C (2008) Perturbation of mouse glioma MRS pattern by induced acute hyperglycemia. NMR Biomed Mar;21(3):251–264.

  15. Mangiola A, Saulnier N, De Bonis P, Orteschi D, Sica G, Lama G, et al. (2013) Gene expression profile of glioblastoma peritumoral tissue: an ex vivo study. PLoS One 8:e57145.

  16. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254

    Article  CAS  PubMed  Google Scholar 

  17. Lama G, Mangiola A, Anile C, Sabatino G, De Bonis P, Lauriola L, et al. (2007) Activated ERK1/2 expression in glioblastoma multiforme and peritumor tissue. Int J Oncol 30:1333–1342

    CAS  PubMed  Google Scholar 

  18. Plotnikov A, Chuderland D, Karamansha Y, Livnah O, Seger R (2011) Nuclear extracellular signal-regulated kinase 1 and 2 translocation is mediated by casein kinase 2 and accelerated by autophosphorylation. Mol Cell Biol 31(17):3515–3530

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Agarwal M, Nitta RT, Li G (2014) Casein kinase 2: A novel player in glioblastoma therapy and cancer stem cells. Mol Genet Med 8:pii: 1000094.

  20. Zheng Y, McFarland BC, Drygin D, Yu H, Bellis SL, Kim H, et al. (2013) Targeting protein kinase CK2 supresses prosurvival signaling pathways and growth of glioblastoma. Clin Cancer Res 19(23):6484–6494

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

This work was supported by: SAF 2011-23870, SAF2014-52332-R, SGR191-2014 and Centro de Investigación Biomédica en Red – Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN, [http://www.ciber-bbn.es/en]), an initiative of the Instituto de Salud Carlos III (Spain) co-funded by EU FEDER funds.

Conflict of interest diclosures

The authors have no financial conflicts to disclose.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Ana Paula Candiota.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ferrer-Font, L., Alcaraz, E., Plana, M. et al. Protein Kinase CK2 Content in GL261 Mouse Glioblastoma. Pathol. Oncol. Res. 22, 633–637 (2016). https://doi.org/10.1007/s12253-015-9987-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12253-015-9987-7

Keywords

Navigation